Pharmacoeconomic evaluation of treatments for Poly Cystic Ovarian Syndrome (PCOS).

IF 1.7 4区医学 Q3 HEALTH POLICY & SERVICES Cost Effectiveness and Resource Allocation Pub Date : 2024-09-05 DOI:10.1186/s12962-024-00569-6

Darakhshan Masroor, Sheikh Abdul Khaliq, Syed Muzzammil Ahmad, Farah Mazhar, Iqbal Azhar

{"title":"Pharmacoeconomic evaluation of treatments for Poly Cystic Ovarian Syndrome (PCOS).","authors":"Darakhshan Masroor, Sheikh Abdul Khaliq, Syed Muzzammil Ahmad, Farah Mazhar, Iqbal Azhar","doi":"10.1186/s12962-024-00569-6","DOIUrl":null,"url":null,"abstract":"Background: Treatment cost and high prevalence of Poly Cystic Ovarian Syndrome (PCOS) is a very challenging issue globally. Due to this reason; current study was conducted to determine pharmaco-economy of conventional and non-conventional treatments for the management of PCOS.Methods: Prospective Cross-Sectional study was conducted in the metropolitan city of Karachi from January - December 2019. Primary data of 200 PCOS patients were collected from different hospitals and clinics. An instrument was used to collect data pertaining to the direct and indirect cost associated with the disease management. Collected data was analyzed by the tools for cost analysis and software called Statistical Package of Social Sciences (SPSS) - 22.Results: In Cost Minimization Analysis (CMA); Allopathic treatment [Mean cost/month: PKR:4479.32 ± 350.95 (USD:27.46 ± 2.15)], Herbal treatment [Mean cost/month: PKR:1527.78 ± 78.15 (USD:9.37 ± 0.48)], Combination treatment [Mean cost/month: PKR:2803.09 ± 654.22 (USD:17.18 ± 4.01)], and Homoeopathic treatment [Mean cost/month: PKR:976.95 ± 46.19 (USD:5.99 ± 0.28)]. Incremental cost/month for Allopathic treatment is 358%, Herbal treatment is 56%, Combination treatment is 187%. In Cost Effectiveness Analysis (CEA); Allopathic treatment (Incremental cost-effectiveness ratio/month: 1334.24), Herbal treatment (Incremental cost-effectiveness ratio/month: 936.41), Combination treatment (Incremental cost-effectiveness ratio/month: 1017.09). Due to lowest cost of Homeopathic treatment, cost of Homeopathic treatment was considered as a threshold value. In-direct cost/month of Allopathic treatment is PKR:593.33 ± 24.00 (USD:3.64 ± 0.15), Herbal treatment is PKR:307.84 ± 26.69 (USD:1.89 ± 0.16), Combination treatment is PKR:409.09 ± 45.63 (USD:2.51 ± 0.28) and Homoeopathic treatment is PKR:300.00 ± 26.39 (USD:1.84 ± 0.16).Conclusion: The most cost-effective is treatment is Homeopathic; Herbal treatment is second most cost-effective option for the treatment of PCOS. Lowest direct and indirect costs and short treatment duration collaboratively lessen the %incremental cost per year and incremental cost effectiveness ratio per year.","PeriodicalId":47054,"journal":{"name":"Cost Effectiveness and Resource Allocation","volume":"22 1","pages":"62"},"PeriodicalIF":1.7000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378486/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cost Effectiveness and Resource Allocation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12962-024-00569-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Treatment cost and high prevalence of Poly Cystic Ovarian Syndrome (PCOS) is a very challenging issue globally. Due to this reason; current study was conducted to determine pharmaco-economy of conventional and non-conventional treatments for the management of PCOS.

Methods: Prospective Cross-Sectional study was conducted in the metropolitan city of Karachi from January - December 2019. Primary data of 200 PCOS patients were collected from different hospitals and clinics. An instrument was used to collect data pertaining to the direct and indirect cost associated with the disease management. Collected data was analyzed by the tools for cost analysis and software called Statistical Package of Social Sciences (SPSS) - 22.

Results: In Cost Minimization Analysis (CMA); Allopathic treatment [Mean cost/month: PKR:4479.32 ± 350.95 (USD:27.46 ± 2.15)], Herbal treatment [Mean cost/month: PKR:1527.78 ± 78.15 (USD:9.37 ± 0.48)], Combination treatment [Mean cost/month: PKR:2803.09 ± 654.22 (USD:17.18 ± 4.01)], and Homoeopathic treatment [Mean cost/month: PKR:976.95 ± 46.19 (USD:5.99 ± 0.28)]. Incremental cost/month for Allopathic treatment is 358%, Herbal treatment is 56%, Combination treatment is 187%. In Cost Effectiveness Analysis (CEA); Allopathic treatment (Incremental cost-effectiveness ratio/month: 1334.24), Herbal treatment (Incremental cost-effectiveness ratio/month: 936.41), Combination treatment (Incremental cost-effectiveness ratio/month: 1017.09). Due to lowest cost of Homeopathic treatment, cost of Homeopathic treatment was considered as a threshold value. In-direct cost/month of Allopathic treatment is PKR:593.33 ± 24.00 (USD:3.64 ± 0.15), Herbal treatment is PKR:307.84 ± 26.69 (USD:1.89 ± 0.16), Combination treatment is PKR:409.09 ± 45.63 (USD:2.51 ± 0.28) and Homoeopathic treatment is PKR:300.00 ± 26.39 (USD:1.84 ± 0.16).

Conclusion: The most cost-effective is treatment is Homeopathic; Herbal treatment is second most cost-effective option for the treatment of PCOS. Lowest direct and indirect costs and short treatment duration collaboratively lessen the %incremental cost per year and incremental cost effectiveness ratio per year.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多囊卵巢综合症 (PCOS) 治疗方法的药物经济学评估。

背景：多囊卵巢综合症（PCOS）的治疗费用和高发病率是一个极具挑战性的全球性问题。因此，本研究旨在确定治疗多囊卵巢综合症的常规和非常规疗法的药物经济性：方法：2019 年 1 月至 12 月在卡拉奇大都市进行了前瞻性横断面研究。从不同的医院和诊所收集了 200 名多囊卵巢综合征患者的原始数据。使用一种工具收集与疾病管理相关的直接和间接成本数据。收集到的数据通过成本分析工具和社会科学统计软件包（SPSS）- 22 进行分析：在成本最小化分析（CMA）中，对抗疗法[平均成本/月：4 479.32 PKR ± 350.95（27.46 ± 2.15 美元）]、草药治疗[平均成本/月：1 527.78 PKR ± 78.15（9.平均费用/月：巴基斯坦卢比：1527.78 ± 78.15（美元：9.37 ± 0.48）]、联合治疗[平均费用/月：巴基斯坦卢比：2803.09 ± 654.22（美元：17.18 ± 4.01）]和同种疗法[平均费用/月：巴基斯坦卢比：976.95 ± 46.19（美元：5.99 ± 0.28）]。对症治疗的增量成本/月为 358%，草药治疗为 56%，联合治疗为 187%。在成本效益分析中，对抗疗法（增量成本效益比/月：1334.24）、草药疗法（增量成本效益比/月：936.41）、联合疗法（增量成本效益比/月：1017.09）。由于顺势疗法的成本最低，因此顺势疗法的成本被视为阈值。对症治疗的直接成本/月为 593.33 PKR ± 24.00（3.64 ± 0.15 美元），草药治疗的直接成本/月为 307.84 PKR ± 26.69（1.89 ± 0.16 美元），综合治疗的直接成本/月为 409.09 PKR ± 45.63（2.51 ± 0.28 美元），同种疗法的直接成本/月为 300.00 PKR ± 26.39（1.84 ± 0.16 美元）：顺势疗法是最具成本效益的治疗方法；草药治疗是治疗多囊卵巢综合症的第二大成本效益选择。最低的直接和间接成本以及较短的疗程共同降低了每年的增量成本%和每年的增量成本效益比。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cost Effectiveness and Resource Allocation HEALTH POLICY & SERVICES-

CiteScore

3.40

自引率

4.30%

发文量

审稿时长

34 weeks

期刊介绍： Cost Effectiveness and Resource Allocation is an Open Access, peer-reviewed, online journal that considers manuscripts on all aspects of cost-effectiveness analysis, including conceptual or methodological work, economic evaluations, and policy analysis related to resource allocation at a national or international level. Cost Effectiveness and Resource Allocation is aimed at health economists, health services researchers, and policy-makers with an interest in enhancing the flow and transfer of knowledge relating to efficiency in the health sector. Manuscripts are encouraged from researchers based in low- and middle-income countries, with a view to increasing the international economic evidence base for health.